Show simple item record

dc.contributor.authorGoll, Rasmus
dc.contributor.authorJohnsen, Peter Holger
dc.contributor.authorHjerde, Erik
dc.contributor.authorDiab, Joseph
dc.contributor.authorValle, Per Christian
dc.contributor.authorHilpüsch, Frank
dc.contributor.authorCavanagh, Jorunn Pauline
dc.date.accessioned2021-04-26T07:25:12Z
dc.date.available2021-04-26T07:25:12Z
dc.date.issued2020-09-29
dc.description.abstractIrritable bowel syndrome (IBS) is a common disorder of the lower gastrointestinal tract. The pathophysiology is far from settled, but a gut microbial dysbiosis is hypothesized to be a contributing factor. We earlier published a randomized double-blind placebo-controlled clinical trial on fecal microbiota transplantation (FMT) for IBS – the REFIT trial. The present data set describes the engraftment and includes participants from the study who received active FMT; 14 participants with effect of FMT (<i>Effect</i>) and 8 without (<i>No effect</i>). Samples were collected at baseline, after 6 and 12 months. Samples from the transplants (<i>Donor</i>) served as a comparator. In total 66 recipient samples and 17 donor samples were subjected to deep metagenomic sequencing, and taxonomic and functional analyses were performed. Alpha diversity measures showed a significantly increased diversity and evenness in the IBS groups compared to the donors. Taxonomic profiles showed higher relative abundance of phylum Firmicutes, and lower relative abundance of phylum Bacteroidetes, compared to donors at baseline. This profile was shifted toward the donor profile following FMT. Imputed growth rates showed that the resulting growth pattern was a conglomerate of donor and recipient activity. Thirty-four functional subclasses showed distinct differences between baseline samples and donors, most of which were shifted toward a donor-like profile after FMT. All of these changes were less pronounced in the <i>No effect</i> group. We conclude that FMT induces long-term changes in gut microbiota, and these changes mirror the clinical effect of the treatment. The study was registered in ClinicalTrials.gov (NCT02154867).en_US
dc.identifier.citationGoll, Johnsen, Hjerde, Diab, Valle, Hilpüsch, Cavanagh. Effects of fecal microbiota transplantation in subjects with irritable bowel syndrome are mirrored by changes in gut microbiome. Gut microbes. 2020;12:e1794263(1):1-15en_US
dc.identifier.cristinIDFRIDAID 1838853
dc.identifier.doi10.1080/19490976.2020.1794263
dc.identifier.issn1949-0976
dc.identifier.issn1949-0984
dc.identifier.urihttps://hdl.handle.net/10037/21040
dc.language.isoengen_US
dc.publisherTaylor & Francisen_US
dc.relation.journalGut microbes
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2020 The Author(s)en_US
dc.subjectVDP::Medical disciplines: 700en_US
dc.subjectVDP::Medisinske Fag: 700en_US
dc.titleEffects of fecal microbiota transplantation in subjects with irritable bowel syndrome are mirrored by changes in gut microbiomeen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record